HENGRUI Aktie

 

HENGRUI PHARMA (01276.HK) disclosed in a filing that it repurchased 250,000 HENGRUI PHARMA (600276.SH) A shares on the Shanghai Stock Exchange on September 23, at prices ranging from RMB45.42 to RMB45.54 per share, involving approximately RMB11.3723 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automat......

HENGRUI PHARMA (01276.HK) announced that three of its drugs recently received approval notices for drug clinical trials issued by the National Medical Products Administration, with clinical trials to commence in the near term.Among them, the company's self-developed Class 1 innovative drug HRS-1596 tablets received approval to c......

HENGRUI PHARMA (01276.HK) announced that it conducted its first buyback of HENGRUI PHARMA (600276.SH) A-shares yesterday (17th), repurchasing 335,000 shares, representing approximately 0.005% of the company's total share capital. The transaction price ranged from RMB43.1 to RMB43.58 per share, involving approximately RMB14.5036 ......

HENGRUI PHARMA (01276.HK) announced that its subsidiary Guangdong Hengrui Pharmaceutical recently received approval notices for drug clinical trials issued by the National Medical Products Administration, agreeing to the commencement of Phase III clinical trials for Recaticimab for Injection, which is expected to begin in the ne......

HENGRUI PHARMA (01276.HK) announced that it received notification from China's National Medical Products Administration approving two additional indications for HETROMB tablets, a Class 1 innovative drug independently developed by the company.The newly approved indications include treatment of adult patients with chemotherapy-in......

HENGRUI PHARMA (01276.HK) announced that its subsidiary Fujian Shengdi Pharmaceutical received a Notice of Acceptance issued by the National Medical Products Administration, under which the marketing authorization application for the company's Reporpetide Injection has been accepted by the regulator. The drug is intended for blo......

A group of Hong Kong-listed biotechnology companies have seen their stock prices surge in the wake of Moderna's breakthrough cancer vaccine trial, as the Chinese companies push forward with similar vaccine programmes. The companies – from Jiangsu Hengrui Pharmaceuticals to Li Ka-shing-backed CK Life Sciences – already have a slew of cancer vaccines in development, which could have a large potential market given that nearly 2.6 million people die from cancer in China alone each year. “China is......

BOCOM International issued a report saying that HENGRUI PHARMA (01276.HK)'s existing business came under pressure in the first half, while innovative drugs maintained solid growth. The company's revenue for the first half fell 2% YoY to RMB15.46 billion, of which product sales rose 2%. Revenue from innovative drugs increased 16%......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

HSBC Global Investment Research issued a report saying that HENGRUI PHARMA (01276.HK)'s 1H26 results missed market expectations due to policy uncertainty and intense domestic competition. However, comprehensive global Phase III pipeline progress is expected to support a re-rating of the stock. The broker maintained its Buy ratin......

HENGRUI PHARMA (01276.HK) announced that its subsidiary Chengdu Shengdi received notification from the National Medical Products Administration approving the market launch of the company's self-developed Class 1 innovative drug fumarate limikopan (HRS-5965) capsules. The approved indication is for the treatment of adult patients......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

HENGRUI PHARMA (01276.HK) announced its interim results for the six months ended June 2026. Revenue amounted to RMB15.456 billion, down 1.9% YoY. Net profit rose 0.3% YoY to RMB4.465 billion, while EPS was RMB0.68. No interim dividend was declared.During the period, product sales revenue increased 1.9% YoY to RMB13.948 billion. ......

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to......

HENGRUI PHARMA (01276.HK) announced that its subsidiary Fujian Shengdi received a notice from the National Medical Products Administration approving the clinical trial application for HRS-4729 injection. The company will soon commence a Phase II clinical trial involving adult patients with type 2 diabetes.In addition, subsidiary......

HENGRUI PHARMA (01276.HK) announced that it recently received notification from the National Medical Products Administration approving the fifth additional indication for its self-developed Category 1 innovative drug Ivarmacitinib Sulfate Tablets (SHR0302 Tablets), for the treatment of adult patients with active non-radiographic......

HENGRUI PHARMA (01276.HK) announced that subsidiaries Suzhou Shengdiya and Shanghai Shengdi have received notices from the National Medical Products Administration approving a Phase II clinical trial for injectable SHR-A2009 in combination with adebrelimab, or in combination with third-generation EGFR TKI, in patients with non-s......

METIS TECHBIO-P (07666.HK) announced a cooperation agreement with HENGRUI PHARMA (01276.HK), under which its self-developed AiTEM artificial intelligence formulation innovation platform will be deployed locally at HENGRUI PHARMA to accelerate the efficiency of drug formulation development. The cooperation marks the continued rea......

HENGRUI PHARMA (01276.HK) announced that it recently received notification from the National Medical Products Administration approving the launch of the company's self-developed Class 1 therapeutic biological product, Shudi Insulin Injection, in China. The product is China's first self-developed long-acting insulin analog.In add......